Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adoxa · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Doxycycline Tablets, 150mg |
| 2 | ACTIVE_COMPARATOR | Adoxa Tablets 150 mg |
| Name | Type | Description |
|---|---|---|
| Doxycycline Tablets, 150mg | DRUG | 150mg, single dose fasting |
| Adoxa Tablets 150 mg | DRUG | 150mg, single dose fasting |
| Doxycycline Monohydrate Tablets 100 mg | DRUG | 100mg, single dose fed |
| Adoxa Tablets 100 mg | DRUG | 100mg, single dose fed |
| Doxycycline Monohydrate Tablets (100 mg | DRUG | 100mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 21 days prior to the start of the study and on the ev...
Adoxa is a small molecule drug being developed by Viatris Inc. (VTRS). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, with three completed trials involving a total of 107 participants. These trials were conducted in the United States.
Adoxa has been studied in healthy volunteers, meaning it is not being tested for a specific disease or condition. The clinical trials for Adoxa focused on pharmacokinetic parameters, such as the effects of food and fasting on the drug's absorption. It is not approved for any medical indication.
Adoxa is developed by Viatris Inc., a company traded on the stock exchange under the ticker symbol VTRS. Viatris is the developer of this drug, which is currently in Phase 1 clinical development.
Adoxa is in Phase 1 clinical development. All three of its clinical trials have been completed, with no active trials currently ongoing. The drug is investigational and has not been approved by regulatory authorities.
Adoxa has been studied in three completed Phase 1 trials: NCT00647959, a fasting study of doxycycline monohydrate tablets 150 mg and Adoxa tablets 150 mg; NCT00648180, a food study of doxycycline monohydrate tablets 100 mg and Adoxa tablets 100 mg; and NCT00649571, a fasting study of doxycycline monohydrate tablets 100 mg and Adoxa tablets 100 mg. All trials enrolled healthy adults aged 18 years and older in the United States.
Adoxa is a brand name for doxycycline monohydrate, a type of tetracycline antibiotic. The clinical trials for Adoxa compared it directly with doxycycline monohydrate tablets, indicating that Adoxa is a formulation of doxycycline. However, Adoxa is not approved for any indication and is still in clinical development.